



HEINZ VETTERLI
Heinz has haemophilia A
and lives in Switzerland.

Novo Nordisk Satellite Symposium

Part of the 13th Annual Congress of the European Association for
Haemophilia and Allied Disorders (EAHAD) | The Hague, The Netherlands

Esperoct[®] (turoctocog alfa pegol), a new extended half-life rFVIII: Continuing the commitment to patients with haemophilia A

Wednesday, 5 February 2020; 15:30 – 16:45 h
Venue: World Forum, The Hague, The Netherlands
Room: Atlantic Room

Please join us!



Esperoct® (turoctocog alfa pegol), a new extended half-life rFVIII: Continuing the commitment to patients with haemophilia A

Agenda

Wednesday, 5 February 2020; 15:30 – 16:45 h

Welcome & introduction	Symposium Chair Pratima Chowdry <i>London, UK</i>
Esperoct®: A new extended half-life rFVIII for haemophilia A	Stephanie Seremetis <i>Princeton, NJ, USA</i>
Esperoct®: From clinical development to clinical practice An interactive discussion	Pratima Chowdry <i>London, UK</i> Andreas Tiede <i>Hannover, Germany</i> Sonata Šaulytė Trakymiene <i>Vilnius, Lithuania</i>
Q&A, discussion & final remarks	All and Chair

An interactive scientific symposium supported by Novo Nordisk.

In the USA, Canada, Japan and Switzerland, Esperoct® (turoctocog alfa pegol, N8-GP) is indicated for use in adults and children with haemophilia A for: on-demand treatment and control of bleeding episodes; perioperative management of bleeding; and routine prophylaxis to reduce the frequency of bleeding episodes. In the European Union, Esperoct® is indicated for use in adults and adolescents (≥12 years of age) with haemophilia A for: prophylaxis and on-demand treatment of bleeding; and surgical procedures.

Please note that Esperoct® may not yet be available in your country. Please always consult your local prescribing information as licenses and licensing conditions may vary from country to country; local prescribing information should be adhered to at all times.